{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:50:58Z","timestamp":1773525058890,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Trastuzumab-deruxtecan (T-DXd) is an antibody\u2013drug conjugate (ADC) that revolutionized the treatment approach for breast cancer. However, the infectious risk associated with T-DXd is unknown. Here, we evaluate the infectious risk of T-DXd against trastuzumab-emtansine (T-DM1), an ADC with an identical monoclonal antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of consecutive breast cancer patients who received T-DXd or T-DM1. Demographic data, infection risk factors, infection sites, and opportunistic infections were recorded and compared across treatment groups. Multivariable logistic regression was used to evaluate the association between treatment group and infection, adjusting for clinical risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      374 patients received T-DXd or T-DM1, with 126 receiving T-DXd alone, 196 receiving T-DM1 alone, and 52 patients receiving both treatments. Patients who received T-DXd did so as higher line of therapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), was given more in the palliative setting (100% vs 33.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), had more prior immunosuppressive systemic treatment (78.6% vs 16.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), were exposed to more significant corticosteroid courses (17.2% vs 4.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and had more hospitalizations during treatment (57.3% vs 27.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients treated with T-DXd had a higher incidence of total infections (24.4% vs 14.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01); in the infected population, unadjusted analysis reveals that those treated with T-DXd had more bloodstream infections (33.3% vs 5.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) and more infection-related mortality (18.2% vs 0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Three patients developed opportunistic infections on T-DXd, and 2 of the 3 were treated concurrently with high-dose corticosteroids. For multivariate analysis, after adjustment for clinically relevant variables and those associated with the outcome in univariate analyses, T-DXd was not associated with an increased risk of infection (OR\u2009=\u20091.89, 95% CI: 0.85\u20134.32,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although patients receiving T-DXd had a higher incidence of infection, no significant difference in infectious risk was found after adjusting for several confounding variables. Infection-related mortality and opportunistic infections were rare and only occurred in the T-DXd cohort. Future prospective studies are warranted to more reliably evaluate the infectious risk of T-DXd compared to T-DM1, particularly as T-DXd is increasingly utilized earlier in the treatment course for breast cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07937-1","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:02:40Z","timestamp":1772870560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer"],"prefix":"10.1007","volume":"216","author":[{"given":"Scott","family":"Gayfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Waleski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin R.","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab El","family":"Boghdadly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-4465","authenticated-orcid":false,"given":"Kevin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"7","key":"7937_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab Deruxtecan in previously treated HER2-Positive breast cancer. N Engl J Med 382(7):610\u2013621","journal-title":"N Engl J Med"},{"key":"7937_CR2","doi-asserted-by":"crossref","unstructured":"Modi S, Jacot W, Yamashita, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","DOI":"10.1056\/NEJMoa2203690"},{"issue":"10371","key":"7937_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP et al (2023) Trastuzumab deruxtecan versus Trastuzumab Emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371):105\u2013117","journal-title":"Lancet"},{"issue":"4","key":"7937_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H et al (2022) Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine Trastuzumab Deruxtecan monotherapy studies. ESMO Open 7(4):100554","journal-title":"ESMO Open"},{"issue":"1","key":"7937_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13058-025-01967-1","volume":"27","author":"J Henricks","year":"2025","unstructured":"Henricks J, Haddad T, Ahmed O et al (2025) Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer. Breast Cancer Res 27(1):16","journal-title":"Breast Cancer Res"},{"issue":"11","key":"7937_CR6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","volume":"47","author":"Z Guo","year":"2022","unstructured":"Guo Z, Ding Y, Wang M et al (2022) Safety of Trastuzumab Deruxtecan: a meta-analysis and pharmacovigilance study. J Clin Pharm Ther 47(11):1837\u20131844","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"7937_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","volume":"22","author":"P Ma","year":"2023","unstructured":"Ma P, Tian H, Shi Q et al (2023) High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database. Expert Opin Drug Saf 22(8):685\u2013696","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"7937_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"key":"7937_CR9","doi-asserted-by":"crossref","unstructured":"PA Harris, R Taylor, BL Minor et al (2019) REDCap Consortium,\u00a0The REDCap consortium: Building an international community of software partners. J Biomed Inform.","DOI":"10.1016\/j.jbi.2019.103208"},{"issue":"3","key":"7937_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/21505594.2016.1152440","volume":"7","author":"C Viscoli","year":"2016","unstructured":"Viscoli C (2016) Bloodstream Infections: The peak of the iceberg. Virulence 7(3):248\u2013251","journal-title":"Virulence"},{"issue":"7","key":"7937_CR11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2022.05.013","volume":"40","author":"O Lyudovyk","year":"2022","unstructured":"Lyudovyk O, Kim JY, Qualls D, Hwee MA, Lin YH, Boutemine SR, Elhanati Y, Solovyov A, Douglas M, Chen E, Babady NE, Ramanathan L, Vedantam P, Bandlamudi C, Gouma S, Wong P, Hensley SE, Greenbaum B, Huang AC, Vardhana SA (2022) Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell 40(7):738-753.e5","journal-title":"Cancer Cell"},{"issue":"10","key":"7937_CR12","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/apa.15955","volume":"110","author":"A Psaros Einberg","year":"2021","unstructured":"Psaros Einberg A, Casswall TH, Arnell H, Nowak G, Mirazimi A, Sundin M, Fischler B (2021) Iatrogenic immunosuppression can lead to prolonged viral shedding and absent immune response to COVID-19. Acta Paediatr 110(10):2810\u20132811","journal-title":"Acta Paediatr"},{"issue":"2","key":"7937_CR13","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF et al (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious diseases society of America. Clin Infect Dis 59(2):e10-52","journal-title":"Clin Infect Dis"},{"key":"7937_CR14","doi-asserted-by":"crossref","unstructured":"Trautner BW, Cort\u00e9s-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, Colgan R, O'Horo JC, Ashraf MS, Connolly S, Drekonja D, Grigoryan L, Huttner A, Lazenby GB, Nicolle L, Schaeffer A, Yawetz S, Lavergne V (2025) Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI. Clin Infect Dis 19:ciaf461.","DOI":"10.1093\/cid\/ciaf461"},{"issue":"1","key":"7937_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"12","key":"7937_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA (2022) Destiny-breast03 trial investigators trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154","journal-title":"N Engl J Med"},{"key":"7937_CR17","doi-asserted-by":"publisher","first-page":"S1671","DOI":"10.1016\/j.annonc.2025.09.021","volume":"36","author":"CE Geyer","year":"2025","unstructured":"Geyer CE, Park YH, Shao Z-M, Huang C-S, Barrios CHE, Abraham J, Prat A, Niikura N, Untch M, Im S-A, Li W, Li H, Wang Y, Yao H, Kim S-B, Mathias E, Sato Y, Lu W, Abdel-Monem H, Loibl S (2025) LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): interim analysis of DESTINY-Breast05. Ann Oncol 36:S1671\u2013S1672","journal-title":"Ann Oncol"},{"issue":"12","key":"7937_CR18","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM et al (2024) Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med 30(12):3717\u20133727","journal-title":"Nat Med"},{"issue":"1","key":"7937_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/ofid\/ofad639","volume":"11","author":"N Quigley","year":"2023","unstructured":"Quigley N, d\u2019Amours L, Gervais P, Dion G (2023) Epidemiology, risk factors, and prophylaxis use for pneumocystis jirovecii pneumonia in the non-HIV population: a retrospective study in Qu\u00e9bec Canada. Open Forum Infect Dis 11(1):639","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"7937_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2334-4-42","volume":"16","author":"E Sowden","year":"2004","unstructured":"Sowden E, Carmichael AJ (2004) Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 16(4):42","journal-title":"BMC Infect Dis"},{"issue":"12","key":"7937_CR21","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","volume":"12","author":"G Jerusalem","year":"2022","unstructured":"Jerusalem G, Park YH, Yamashita T et al (2022) Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A destiny-breast01 subgroup analysis. Cancer Discov 12(12):2754\u20132762","journal-title":"Cancer Discov"},{"issue":"8","key":"7937_CR22","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1128\/JCM.41.8.3655-3660.2003","volume":"41","author":"DJ Diekema","year":"2003","unstructured":"Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV (2003) Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 41(8):3655\u20133660","journal-title":"J Clin Microbiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07937-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:02:06Z","timestamp":1773522126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07937-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7937"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07937-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was reviewed and approved by The OSU Institutional Review Board (2023C0104), and a waiver of informed consent was granted due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"23"}}